Response of parkinsonian swallowing dysfunction to dopaminergic stimulation

Hunter, P. C.; Crameri, J.; Austin, S.; Woodward, M. C.; Hughes, A. J.
November 1997
Journal of Neurology, Neurosurgery & Psychiatry;Nov1997, Vol. 63 Issue 5, p579
Academic Journal
journal article
No abstract available.


Related Articles

  • Deranged NMDAergic cortico-subthalamic transmission underlies parkinsonian motor deficits. Ming-Kai Pan; Chun-Hwei Tai; Wen-Chuan Liu; Ju-Chun Pei; Wen-Sung Lai; Chung-Chin Kuo // Journal of Clinical Investigation;Oct2014, Vol. 124 Issue 10, p4629 

    Parkinson's disease (PD) is the most prevalent hypokinetic movement disorder, and symptomatic PD pathogenesis has been ascribed to imbalances between the direct and indirect pathways in the basal ganglia circuitry. Here, we applied glutamate receptor blockers to the subthalamic nucleus (STN) of...

  • Involvement of Non-Dopaminergic Pathways in Parkinson’s Disease: Pathophysiology and Therapeutic Implications. Bonnet, A-M. // CNS Drugs;2000, Vol. 13 Issue 5, p351 

    Parkinson’s disease is primarily characterised by degeneration of the nigrostriatal dopaminergic pathways in the basal ganglia. However, non-dopaminergic neurotransmission is also affected in Parkinson’s disease. The dysfunction of non-dopaminergic systems explains the principal...

  • Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. Chase, T. N.; Oh, J. D.; Konitsiotis, S. // Journal of Neurology;Apr2000 Supplement 2, Vol. 247, pII36 

    Motor dysfunction produced by the chronic non-physiological stimulation of dopaminergic receptors on striatal medium spiny neurons is associated with alterations in the sensitivity of glutamatergic receptors, including those of the N-methyl-D-aspartate (NMDA) subtype. Functional characteristics...

  • Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Booij, Jan; Tissingh, Gerrit; Winogrodzka, Ania; van Royen, Eric A. // European Journal of Nuclear Medicine;1999, Vol. 26 Issue 2, p171 

    Abstract. Parkinsonism is a feature of a number of neurodegenerative diseases, including Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. The results of post-mortem studies point to dysfunction of the dopaminergic neurotransmitter system in patients with...

  • Imaging gait disorders in parkinsonism: a review. Maillet, Audrey; Pollak, Pierre; Debû, Bettina // Journal of Neurology, Neurosurgery & Psychiatry;Oct2012, Vol. 83 Issue 10, p986 

    Gait difficultiesdincluding freezing of gaitdare frequent and disabling symptoms of advanced Parkinson's disease and other parkinsonian syndromes. They respond poorly to current medical and surgical treatments, making patient management very difficult. The underlying pathophysiology remains...

  • Abnormal elevation of resting pressure at the upper esophageal sphincter of Parkinson’s disease patients. Higo, Ryuzaburo; Tayama, Niro; Watanabe, Takeshi; Niimi, Seiji // European Archives of Oto-Rhino-Laryngology;Dec2001, Vol. 258 Issue 10, p552 

    We investigated the oral and pharyngeal swallowing function in seven Parkinson’s disease (PD) patients, using videomanofluorometry, which is videofluorographic and manometric evaluation conducted simultaneously. Abnormal elevations of resting pressure were found at the upper esophageal...

  • Ultrassonografia transcraniana na doença de Parkinson. Bor-Seng-Shu, Edson; Pedroso, José Luiz; de Andrade, Daniel Ciampi; Povoas Barsottini, Orlando Graziani; de Andrade, Luiz Augusto Franco; Barbosa, Egberto Reis; Teixeira, Manoel Jacobsen // Einstein (16794508);abr-jun2012, Vol. 10 Issue 2, p242 

    Transcranial sonography has become a useful tool in the differential diagnosis of parkinsonian syndromes. This is a non-invasive, low cost procedure. The main finding on transcranial sonography in patients with idiopathic Parkinson's disease is an increased echogenicity of the mesencephalic...

  • The Significance of Continuous Dopaminergic Stimulation in the Treatment of Parkinson's Disease. Chase, T.N. // Drugs;Jan1998 Supplement 1, Vol. 55 Issue 1, p1 

    Levodopa continues to be the most effective agent for the symptomatic treatment of Parkinson's disease. No other drug matches its ability to suppress parkinsonian symptoms, especially in patients with advanced disease. But over time, initial benefits begin to wane, not so much because of a...

  • Do Preclinical Findings of Methamphetamine-Induced Motor Abnormalities Translate to an Observable Clinical Phenotype? Caligiuri, Michael P.; Buitenhuys, Casey // Neuropsychopharmacology;Dec2005, Vol. 30 Issue 12, p2125 

    This review summarizes the preclinical literature of the effects of methamphetamine (MA) on subcortical dopaminergic and GABAergic mechanisms underlying motor behavior with the goal of elucidating the clinical presentation of human MA-induced movement disorders. Acute and chronic MA exposure in...

  • PATH54 Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study. K Bhatia // Journal of Neurology, Neurosurgery & Psychiatry;Nov2010, Vol. 81 Issue 11, pe22 

    Approximately 10% of patients diagnosed clinically with early Parkinson's disease (PD) have normal dopaminergic functional imaging (SWEDDs—scans without evidence of dopaminergic deficit). A subgroup of SWEDDs are those with asymmetric tremor resembling parkinsonian tremor. Clinical and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics